DE122005000027I1 - Tricyclische Verbindungen. - Google Patents

Tricyclische Verbindungen.

Info

Publication number
DE122005000027I1
DE122005000027I1 DE200512000027 DE122005000027C DE122005000027I1 DE 122005000027 I1 DE122005000027 I1 DE 122005000027I1 DE 200512000027 DE200512000027 DE 200512000027 DE 122005000027 C DE122005000027 C DE 122005000027C DE 122005000027 I1 DE122005000027 I1 DE 122005000027I1
Authority
DE
Germany
Prior art keywords
alkyl
amino
alkoxy
halogen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE200512000027
Other languages
English (en)
Other versions
DE122005000027I2 (de
Inventor
Jacob Berger
Robin D Clark
Richard M Eglen
William L Smith
Klaus K Weinhardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Palo Alto LLC
Original Assignee
Roche Palo Alto LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23755479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122005000027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Palo Alto LLC filed Critical Roche Palo Alto LLC
Publication of DE122005000027I1 publication Critical patent/DE122005000027I1/de
Publication of DE122005000027I2 publication Critical patent/DE122005000027I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE200512000027 1989-11-28 1990-11-27 Tricyclische Verbindungen. Active DE122005000027I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44208289A 1989-11-28 1989-11-28

Publications (2)

Publication Number Publication Date
DE122005000027I1 true DE122005000027I1 (de) 2005-08-04
DE122005000027I2 DE122005000027I2 (de) 2006-03-16

Family

ID=23755479

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69020694T Expired - Lifetime DE69020694T2 (de) 1989-11-28 1990-11-27 Tricyclische Verbindungen.
DE200512000027 Active DE122005000027I2 (de) 1989-11-28 1990-11-27 Tricyclische Verbindungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69020694T Expired - Lifetime DE69020694T2 (de) 1989-11-28 1990-11-27 Tricyclische Verbindungen.

Country Status (23)

Country Link
US (1) US5202333A (de)
EP (1) EP0430190B1 (de)
JP (1) JPH0662607B2 (de)
KR (1) KR970007917B1 (de)
AT (1) ATE124698T1 (de)
AU (1) AU642178B2 (de)
BR (1) BR1100680A (de)
CA (1) CA2030718C (de)
DE (2) DE69020694T2 (de)
DK (1) DK0430190T3 (de)
ES (1) ES2075121T3 (de)
FI (1) FI98367C (de)
HK (1) HK36097A (de)
HU (1) HU218654B (de)
IE (1) IE68434B1 (de)
IL (2) IL96486A (de)
LU (1) LU91162I2 (de)
NL (1) NL300194I1 (de)
NO (2) NO175309C (de)
NZ (1) NZ236225A (de)
PL (3) PL166267B1 (de)
PT (1) PT96001B (de)
ZA (1) ZA909529B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA909529B (en) * 1989-11-28 1992-08-26 Syntex Inc New tricyclic compounds
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
PT533280E (pt) * 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
NZ257212A (en) * 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
PL179443B1 (pl) * 1994-03-07 2000-09-29 Inhale Therapeutic Syst Kompozycja insuliny, sposób wytwarzania kompozycji insuliny i sposób wytwarzania dawki insuliny w postaci aerozolu PL PL PL PL
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
ES2245780T3 (es) * 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
US5510486A (en) * 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE434437T1 (de) * 1999-02-18 2009-07-15 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
EP1458360B1 (de) 2001-12-19 2011-05-11 Novartis AG Pulmonale verabreichung von aminoglykosiden
EP1478646A1 (de) * 2002-02-20 2004-11-24 PHARMACIA &amp; UPJOHN COMPANY Azabicyclische verbindungen mit activität an alfa7 nikotinischen acetylcholin rezeptoren
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8614225B2 (en) * 2006-08-30 2013-12-24 Dr. Reddy's Laboratories Limited Process for the purification of palonosetron or its salt
US20100016593A1 (en) * 2006-10-23 2010-01-21 Pierluigi Rossetto Crystalline forms of palonosetron hydrochloride
EP1940366B9 (de) * 2006-10-24 2009-12-02 Helsinn Healthcare S.A. Weichkapseln mit palonosetron-hydrochlorid mit verbesserter stabilität und bioverfügbarkeit
EP2099298A4 (de) * 2006-12-07 2010-01-06 Helsinn Healthcare Sa Kristalline und amorphe formen von palonosetron-hydrochlorid
US8334388B2 (en) * 2007-05-29 2012-12-18 Chemagis Ltd. Palonosetron salts and processes for preparation and purification thereof
US20090227623A1 (en) * 2007-09-15 2009-09-10 Protia, Llc Deuterium-enriched palosetron
CN101157691B (zh) * 2007-10-18 2011-01-12 杭州九源基因工程有限公司 一种盐酸帕洛诺司琼的生产工艺
AR069625A1 (es) * 2007-12-13 2010-02-03 Glenmark Generics Ltd Base libre de palonosetron y procedimiento para su preparacion
WO2009087643A1 (en) * 2008-01-11 2009-07-16 Natco Pharma Limited Novel crystalline forms of palonosetron hydrochloride
WO2009136405A1 (en) * 2008-05-05 2009-11-12 Natco Pharma Limited High purity palonosetron base and its solid state characteristics
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
US20100099701A1 (en) * 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
WO2010056656A2 (en) * 2008-11-11 2010-05-20 Dr. Reddy's Laboratories Ltd. Preparation of crystalline palonosetron hydrochloride
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
AU2009324545A1 (en) * 2008-12-11 2011-06-30 A.P. Pharma, Inc. Methods for enhancing stability of polyorthoesters and their formulations
CN101849904A (zh) * 2009-04-03 2010-10-06 南京长澳医药科技有限公司 一种帕洛诺司琼注射液及其制备方法
CN101851233B (zh) * 2009-04-03 2013-03-06 四川滇虹医药开发有限公司 盐酸帕洛诺司琼和其前体化合物及制备
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US8580730B2 (en) 2009-05-20 2013-11-12 (Inserm) Institut National De La Sante Et De La Recherche Medicale Methods of treating lesional vestibular disorders by administering serotonin 5-HT3 receptor antagonists
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
US20120267533A1 (en) 2009-06-30 2012-10-25 Ranbaxy Laboratories Limited Processes for the preparation of form i and form ii of palonosetron hydrochloride
CN102510862A (zh) 2009-07-14 2012-06-20 阿尔巴尼分子研究公司 5-ht3受体调节剂、其制备方法和用途
WO2011013095A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Processes for the preparation of palonosetron
EP2499137A1 (de) * 2009-11-13 2012-09-19 Helsinn Healthcare S.A. Palonosetron-metaboliten
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (de) 2009-11-18 2016-07-06 Helsinn Healthcare SA Zusammensetzungen zur Behandlung von zentral vermitteltem Unwohlsein und Erbrechen
EP2759298B1 (de) 2011-10-18 2018-01-17 Helsinn Healthcare SA Therapeutische Kombinationen von Netupitant und Palonosetron
CN102688185B (zh) * 2012-06-01 2013-07-10 齐鲁制药(海南)有限公司 一种稳定的帕洛诺司琼注射液及其制备方法
CN105934247A (zh) 2013-12-23 2016-09-07 株式会社三养生物制药 包含帕洛诺司琼的药物组合物
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
EP3672964A4 (de) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Neuartige dreifachkombinationsformulierungen für antiemetische therapie
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (de) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidansfreie festdosiskombination aus netupitant und palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385500A1 (de) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Festdosiskombination mit netupitant und palonosetron

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341528A (en) * 1963-11-07 1967-09-12 Warner Lambert Pharmaceutical Substituted benzoquinolines
US3896132A (en) * 1969-08-19 1975-07-22 Hoffmann La Roche Process for preparing 1,2,3,8,9,9a-hexahydro-5,6-dialkoxy-1-alkyl-benzo(d,e)quinolin-7-ore compounds
US4309543A (en) * 1980-03-17 1982-01-05 Dynapol Process for preparing cyclic amides
EP0093488A3 (de) * 1982-03-18 1984-05-23 Beecham Group Plc Nortropyl-Benzopyrrolinon-Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
AU8325987A (en) * 1986-12-11 1988-06-30 Upjohn Company, The Antipsychotic amino-polyhydro-benz-(iso)quinolines and intermediates
EP0315390B1 (de) * 1987-11-04 1994-07-20 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline
ZA909529B (en) * 1989-11-28 1992-08-26 Syntex Inc New tricyclic compounds
AU7618991A (en) * 1990-05-14 1991-11-14 Syntex (U.S.A.) Inc. Novel tricyclic compounds
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists

Also Published As

Publication number Publication date
HK36097A (en) 1997-03-27
NL300194I2 (nl) 2005-07-01
NL300194I1 (nl) 2005-07-01
DK0430190T3 (da) 1995-08-21
IE904269A1 (en) 1991-06-05
CA2030718C (en) 1998-05-12
ZA909529B (en) 1992-08-26
NO2005023I1 (no) 2005-10-03
PL287961A1 (en) 1991-12-02
AU642178B2 (en) 1993-10-14
IL96486A0 (en) 1991-08-16
FI905839A0 (fi) 1990-11-27
IL96486A (en) 1995-03-30
ATE124698T1 (de) 1995-07-15
NO2005023I2 (no) 2009-10-05
US5202333A (en) 1993-04-13
PT96001B (pt) 1998-01-30
PL166272B1 (pl) 1995-04-28
LU91162I2 (fr) 2005-06-20
PT96001A (pt) 1991-09-30
PL166277B1 (pl) 1995-04-28
FI98367B (fi) 1997-02-28
EP0430190A3 (en) 1992-01-22
ES2075121T3 (es) 1995-10-01
DE69020694T2 (de) 1996-01-18
EP0430190B1 (de) 1995-07-05
IE68434B1 (en) 1996-06-12
JPH03176486A (ja) 1991-07-31
KR970007917B1 (ko) 1997-05-17
NO905120L (no) 1991-05-29
FI905839A (fi) 1991-05-29
NO175309C (no) 1994-09-28
NO175309B (no) 1994-06-20
NZ236225A (en) 1992-09-25
DE69020694D1 (de) 1995-08-10
NO905120D0 (no) 1990-11-27
JPH0662607B2 (ja) 1994-08-17
IL110622A (en) 1995-03-30
PL166267B1 (pl) 1995-04-28
HU218654B (hu) 2000-10-28
AU6696390A (en) 1991-06-06
DE122005000027I2 (de) 2006-03-16
CA2030718A1 (en) 1991-05-29
KR910009699A (ko) 1991-06-28
HUT56368A (en) 1991-08-28
BR1100680A (pt) 2000-02-08
FI98367C (fi) 1997-06-10
HU907660D0 (en) 1991-06-28
EP0430190A2 (de) 1991-06-05

Similar Documents

Publication Publication Date Title
ATE124698T1 (de) Tricyclische verbindungen.
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
KR900012911A (ko) 흥분성 아미노산 수용기 길항질 화합물
EA200000391A1 (ru) Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
ATE219766T1 (de) N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
EA199800794A1 (ru) Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
PT753301E (pt) Combinacao de um benzimidazole tendo actividade antagonista da angiotensina ii com um diuretico
TR199801782T2 (xx) Kinoksalindionlar
ID25477A (id) Turunan-turunan spiropiperidin
DE69329184D1 (de) Alkylsubstituierte heterocyclische Verbindungen
TW334428B (en) Novel benzodiazepine derivatives
NO891608D0 (no) Heterotetracykliske laktamderivater.
DE69402703D1 (de) 3-(INDOL-3-YL) PROPENSäURDERIVATE, DIE ALS NMDA- ANTAGONISTEN NÜTZLICH SIND
WO1997029077A1 (fr) Derives amides substitues